Novartis reported robust Q3 2025 results with a 7% increase in sales and core operating income, driven by strong performance from key growth drivers and critical pipeline advancements.
- Core operating income margin held steady at 39.3%, reflecting efficient cost management amid competitive pressures.
- Kisqali saw exceptional growth of 68%, leading in both early and metastatic breast cancer markets, with U.S. sales up 91%.
- Kesimpta experienced 44% growth, bolstered by strong first-line patient access and significant market share in major territories.
- Pluvicto achieved 45% growth, driven by recent approvals and increasing community adoption, supporting a path to peak sales potential.
- Successful FDA approvals and positive Phase III data reinforce Novartis’ growth trajectory and pipeline strength.
Community Discussion